Clinical trial
Study Evaluating Rapamune in Patients After Kidney Transplantation
NCT00240214 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00240214 |
|---|---|
| Title | Study Evaluating Rapamune in Patients After Kidney Transplantation |
| Official title | An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Study type | Observational |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | sirolimus |
| Enrollment | 500 |
| Start date | Apr 1, 2001 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Oct 17, 2005 |
| Last update posted | Mar 14, 2008 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: